Kim SO, Han SY, Baek YH, Lee SW, Han JS, Kim BG, Cho JH, Nam KJ. Splenic infarction associated with sorafenib use in a hepatocellular carcinoma patient. World J Gastroenterol 2011; 17(2): 267-270 [PMID: 21246003 DOI: 10.3748/wjg.v17.i2.267]
Corresponding Author of This Article
Sang Young Han, MD, PhD, Professor, Liver Center, Dong-A University College of Medicine, 3-ga, Dongdaesing-dong, Seo-gu, Busan 602-103, South Korea. syhan@dau.ac.kr
Article-Type of This Article
Case Report
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Jan 14, 2011; 17(2): 267-270 Published online Jan 14, 2011. doi: 10.3748/wjg.v17.i2.267
Splenic infarction associated with sorafenib use in a hepatocellular carcinoma patient
Sang Ock Kim, Sang Young Han, Yang Hyun Baek, Sung Wook Lee, Ji Sun Han, Byung Geun Kim, Jin Han Cho, Kyung Jin Nam
Sang Ock Kim, Sang Young Han, Yang Hyun Baek, Sung Wook Lee, Ji Sun Han, Byung Geun Kim, Department of Gastroenterology and Hepatology, Dong-A University Hospital, Dongdaesin-dong, Seo-gu, Busan 602-103, South Korea
Sang Young Han, Liver Center, Dong-A University College of Medicine, 3-ga, Dongdaesing-dong, Seo-gu, Busan 602-103, South Korea
Jin Han Cho, Kyung Jin Nam, Department of Radiology, Dong-A University Hospital, Dongdaesin-dong, Seo-gu, Busan 602-103, South Korea
Author contributions: Kim SO and Han SY contributed equally to this work; Kim SO, Han SY, Baek YH and Lee SW contributed to drafting the report; Cho JH and Nam KJ interpreted CT images; Kim SO, Han SY and Han JS wrote and revised the paper; all authors contributed to analyzing the patient’s data.
Supported by Dong-A University fund
Correspondence to: Sang Young Han, MD, PhD, Professor, Liver Center, Dong-A University College of Medicine, 3-ga, Dongdaesing-dong, Seo-gu, Busan 602-103, South Korea. syhan@dau.ac.kr
Telephone: +82-51-2402861 Fax: +82-51-2402087
Received: August 15, 2010 Revised: September 26, 2010 Accepted: October 3, 2010 Published online: January 14, 2011
Abstract
Sorafenib, a multitargeted tyrosine kinase inhibitor, has been shown to improve survival in patients with advanced hepatocellular carcinoma (HCC). As the clinical use of sorafenib increases, many adverse effects have been reported, such as hand-foot skin reaction, diarrhea, anorexia, asthenia, alopecia, weight loss, hypertension and arterial thromboembolism. However, there are no prior reports of splenic infarction as an adverse effect of sorafenib. Here, a case of splenic infarction in a patient with HCC who was treated with sorafenib is reported. The patient had no other predisposing factors to explain the splenic infarction except for the administration of sorafenib. The splenic infarction improved after sorafenib was discontinued; however, the HCC progressed.
